User profiles for Brian I Rini
 | Brian RiniVanderbilt University Medical Center Verified email at vumc.org Cited by 81520 |
Renal cell carcinoma
BI Rini, SC Campbell, B Escudier - The Lancet, 2009 - thelancet.com
Considerable progress has been made in the treatment of patients with renal cell carcinoma,
with innovative surgical and systemic strategies revolutionising the management of this …
with innovative surgical and systemic strategies revolutionising the management of this …
[PDF][PDF] Treatment of renal cell carcinoma: current status and future directions
Over the past 12 years, medical treatment for renal cell carcinoma (RCC) has transitioned from
a nonspecific immune approach (in the cytokine era), to targeted therapy against vascular …
a nonspecific immune approach (in the cytokine era), to targeted therapy against vascular …
Resistance to targeted therapy in renal-cell carcinoma
Therapeutic targeting of integral biological pathways, including those involving vascular
endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR), has produced …
endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR), has produced …
Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma
…, Y Tomita, D Castellano, BI Rini… - … England Journal of …, 2018 - Mass Medical Soc
Background Nivolumab plus ipilimumab produced objective responses in patients with
advanced renal-cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus …
advanced renal-cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus …
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
Background Data on patients with COVID-19 who have cancer are lacking. Here we characterise
the outcomes of a cohort of patients with cancer and COVID-19 and identify potential …
the outcomes of a cohort of patients with cancer and COVID-19 and identify potential …
[HTML][HTML] Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma
Background The combination of pembrolizumab and axitinib showed antitumor activity in a
phase 1b trial involving patients with previously untreated advanced renal-cell carcinoma. …
phase 1b trial involving patients with previously untreated advanced renal-cell carcinoma. …
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
BI Rini, B Escudier, P Tomczak, A Kaprin, C Szczylik… - The Lancet, 2011 - thelancet.com
Background The treatment of advanced renal cell carcinoma has been revolutionised by
targeted therapy with drugs that block angiogenesis. So far, no phase 3 randomised trials …
targeted therapy with drugs that block angiogenesis. So far, no phase 3 randomised trials …
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal …
Purpose Renal cell carcinoma (RCC) is characterized by loss of von Hippel Lindau tumor
suppressor gene activity, resulting in high expression of pro-angiogenic growth factors: …
suppressor gene activity, resulting in high expression of pro-angiogenic growth factors: …
[PDF][PDF] Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor–targeted agents: results …
… Rini, and Toni K. Choueiri … Rini Administrative support: Daniel YC Heng, Toni K.
Choueiri … Rini BI, Halabi S, Rosenberg JE, et al: CALGB 90206: A phase III trial of …
Choueiri … Rini BI, Halabi S, Rosenberg JE, et al: CALGB 90206: A phase III trial of …
Sunitinib in patients with metastatic renal cell carcinoma
ContextCurrent treatment options for metastatic renal cell carcinoma (RCC) are limited and
there is a need to identify novel and effective therapies. Sunitinib malate is an oral …
there is a need to identify novel and effective therapies. Sunitinib malate is an oral …
